RET Fusion Targeted Therapies Market Set for Robust Growth by 2034 Amid Precision Oncology Shift | DelveInsight

The RET fusion-targeted therapy market is set for strong expansion, driven by growing awareness of the oncogenic role of RET ...

DelveInsight Business Research, LLP: RET Fusion Targeted Therapies Market Set for Robust Growth by 2034 Amid Precision Oncology Shift | DelveInsight

The RET fusion-targeted therapy market is set for strong expansion, driven by growing awareness of the oncogenic role of RET gene fusions and encouraging clinical trial outcomes. With the approval ...
PharmiWeb

Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

Sixth overall for Lantern’s A.I.-driven precision oncology pipelineOrphan designation expands LP-284's potential for an ...
CURE

FDA Grants Orphan Drug Designation to LP-284 for Soft Tissue Sarcoma

The FDA's orphan drug designation supports LP-284's development for soft tissue sarcomas, addressing significant unmet needs in this adult patient population. The FDA granted orphan drug designation ...
MyChesCo on MSN

Cancer diagnosis enters 3D era as Fox Chase, Arima unite on DNA breakthrough

PHILADELPHIA, PA & CARLSBAD, CA — Fox Chase Cancer Center and Arima Genomics, Inc. have launched a first-of-its-kind ...
Targeted Oncology

Zenocutuzumab Offers Durable Benefit After Progression in NRG1+ GI Tumors

Zenocutuzumab (Bizengri) continued to provide sustained clinical benefit and disease control in patients with advanced NRG1 fusion-positive ( NRG1 +) pancreatic adenocarcinoma (PDAC) and ...
ET HealthWorld

GENETIC TESTING

ETHealthworld.com brings latest genetic testing news, views and updates from all top sources for the Indian Health industry.